ARCT at a glance
Arcturus Therapeutics Holdings Inc. (ARCT, SEC CIK 1768224) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as June 15, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Arcturus Therapeutics Holdings Inc. (ARCT) reported revenue of $82.0 million (down 46.1% from FY2024) and a net loss of $65.8 million. Diluted EPS was -$2.40.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Arcturus Therapeutics Holdings Inc. (ARCT) shares worth $188.5 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $82.0M
- −46.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $188.5M · −1 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 7.01 · Item 3.02 · Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $18.3M, up $1.1M YoY from $17.2M, driven by $16.8M CSL termination-related collaboration revenue
- Collaboration revenue $16.9M vs $14.2M; grant revenue $1.4M vs $3.0M, down 52% YoY
- Operating expenses $27.5M, down 18% YoY, including R&D $17.0M vs $23.3M
- Cash $184.8M at September 30; nine-month operating cash use $46.3M vs $58.0M
- Outlook: cash expected sufficient through at least next twelve months; additional capital anticipated, with continued losses and clinical-development spending
Risk Factors
- CSL Seqirus termination: Arcturus now funds vaccine programs without milestone payments, research funding, or profit sharing
- KOSTAIVE Japan transition: CSL Seqirus and Meiji remain responsible through June 30, 2027, creating transfer disruption risk
- myNEO acquisition: Integration requires compliance with Belgian data privacy, employment, and tax laws
- myNEO acquisition: Unregistered shares and potential milestone shares may dilute existing stockholders
- Middle East conflicts: Regional disruptions could affect international clinical sites, including Israel
AI summary of the ARCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Press release announces transactions with Meiji, signaling a potentially material strategic or commercial development
- Exhibit 99.1 contains the transaction terms investors need to assess financial and operational impact
Item 3.02: Unregistered Sales of Equity Securities
- Unregistered share issuance under Section 4(a)(2), indicating a private placement exempt from Securities Act registration
- Shares subject to resale restrictions until registration or another exemption applies
Item 1.01: Entry into a Material Definitive Agreement
- $50.0M equity sale to Meiji at an 80% premium, providing non-dilutive-to-cash funding but issuing 2,466,395 shares
- Meiji’s ARCT-154 license covers an undisclosed therapeutic area, with Meiji funding development and commercialization
Item EX-99.1: Item EX-99.1
- $50M Meiji equity investment at $20.27 per share, an 80% premium and 7.9% post-transaction ownership
- Proceeds earmarked to accelerate ARCT-2601 development for OTC deficiency and clinically validate LUNAR 2.0
Item 2.02: Results of Operations and Financial Condition
- Arcturus reported financial results for the quarter ended September 30, 2026
- Corporate update covers ARCT-032, ARCT-810, ARCT-2601 and the LUNAR 2.0™ platform
Item EX-99.1: Item EX-99.1
- Q3 revenue $18.3M, up from $17.2M, boosted by the $12.0M CSL Seqirus termination payment
- Cash $184.8M, down $46.1M from December 31, 2025, with management projecting runway through year-end 2028
Item EX-99.1: Item EX-99.1
- ARCT-810 Phase 2 interim data showed favorable safety and improved ammonia and glutamine biomarkers, supporting continued clinical development
- LUNAR 2.0 delivered 40-fold higher hEPO expression and 38-fold higher hOTC potency than comparators in NHP studies
Item 7.01: Regulation FD Disclosure
- Arcturus presented Phase 2 clinical data for ARCT-810, providing investors an update on the program’s development progress
- Management also updated its mRNA delivery platform, relevant to the company’s broader pipeline and technology value
AI summaries of ARCT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ARCT
Don't miss the next ARCT filing
- Alerts as it files. A push when ARCT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ARCT, by share count.
- Ask anything. An AI agent that reads every ARCT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Marquet Magda | A | Jun 5, 2026 | 15,000 | - |
| HOLMES EDWARD W | A | Jun 5, 2026 | 15,000 | - |
| Marantz Jing L. | A | Jun 5, 2026 | 15,000 | - |
| BARLOW JAMES F | A | Jun 5, 2026 | 15,000 | - |
| FARRELL PETER C | A | Jun 5, 2026 | 15,000 | - |
| Markels John | A | Jun 5, 2026 | 15,000 | - |
| Slaoui Moncef | A | Jun 5, 2026 | 15,000 | - |
| MULROY DENNIS | A | May 1, 2026 | 100,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $166.8M | $152.3M | $82.0M |
| Operating Income | -$78.2M | -$95.7M | -$76.3M |
| Net Income | - | -$80.9M | -$65.8M |
| Op. Margin | -46.9% | -62.8% | -93.0% |
| Net Margin | - | -53.1% | -80.2% |
| Balance Sheet | |||
| Total Assets | - | $344.1M | $271.1M |
| Equity | $278.5M | $241.0M | $214.0M |
| ROE | - | -33.6% | -30.7% |
| Per Share | |||
| EPS | $-1.12 | $-3.00 | $-2.40 |
| Cash Flow | |||
| Operating CF | - | -$59.7M | -$74.3M |
| CapEx | - | $648K | $230K |
Source: XBRL data in Arcturus Therapeutics Holdings Inc. (ARCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ARCT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $188.5M |
| Q2 2026 | 27 | $81.5M |
| Q1 2026 | 25 | $88.6M |
| Q4 2025 | 25 | $67.4M |
| Q3 2025 | 25 | $199.7M |
| Q2 2025 | 25 | $136.2M |
| Q1 2025 | 23 | $90.7M |
| Q4 2024 | 17 | $115.0M |
- D.E. Shaw & Co+583.8K (+149%)
- Bank of America Corp+345.7K (+1537%)
- JPMorgan Chase & Co+174.7K (+89%)
- Two Sigma Investments+140.7K (+13%)
- Invesco Ltd+103.8K (+100%)
- Vanguard Portfolio Management LLC−90.3K (-9%)
- AQR Capital Management−59.8K (-9%)
- Goldman Sachs Group−38.1K (-12%)
- Vanguard Capital Management LLC−7.9K (-1%)
- Dimensional Fund Advisors−3.3K (-1%)
- Franklin Resources+174.9K
- Citadel Advisors LLC−40.9K
- FMR LLC (Fidelity)−19.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 193 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ARCT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 8-K | Aug 25, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | May 7, 2026 | - | - | |
| 10-K | Mar 3, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 3, 2026 | - | Analysis | - |
| 4 | Dec 19, 2025 | - | - | |
| 4 | Dec 19, 2025 | - | - | |
| 4 | Dec 19, 2025 | - | - | |
| 4 | Dec 19, 2025 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ARCT SEC filings: frequently asked questions
Which institutions hold ARCT stock?
As of September 30, 2026, the largest Arcturus Therapeutics Holdings Inc. (ARCT) holders among the 13F filers tracked by SignalX were ARK Investment Management ($41.0 million), BlackRock ($36.9 million), Two Sigma Investments ($16.9 million), Vanguard Capital Management LLC ($15.2 million), D.E. Shaw & Co ($13.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ARCT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Arcturus Therapeutics Holdings Inc. (ARCT) reported revenue of $82.0 million (down 46.1% from FY2024) and a net loss of $65.8 million. Diluted EPS was -$2.40. The figures come from the XBRL data in the 10-K.
What did ARCT report in its latest 8-K?
Arcturus Therapeutics Holdings Inc. (ARCT) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 3.02 (Unregistered Sales of Equity Securities) and Item 1.01 (Entry into a Material Definitive Agreement). Press release announces transactions with Meiji, signaling a potentially material strategic or commercial development.
What are the latest ARCT SEC filings?
Arcturus Therapeutics Holdings Inc. (ARCT) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on June 15, 2026.
What is ARCT's SEC CIK number?
Arcturus Therapeutics Holdings Inc. (ARCT)'s SEC Central Index Key (CIK) is 1768224. EDGAR lists every ARCT filing under that number.
Ask anything about ARCT
The research agent reads ARCT's filings, financials, insider trades and 13F holders, then answers with sources.